Stock CERENIS THERAPEUTICS
Add to a list
To use this feature you must be a member
Log inSign up

Cerenis Therapeutics Share Price LIQUIDNET SYSTEMS

Equities

FR0012616852

Biotechnology & Medical Research

End-of-day quote LIQUIDNET SYSTEMS
Other stock markets
 		5-day change 1st Jan Change
- EUR -.--% Intraday chart for Cerenis Therapeutics -.--% -.--%
06-14 Abionyx: positive response from FDA, share price rises CF
06-13 ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis CI

Financials

Sales 2024 * 4.6M 4.92M 389M Sales 2025 * 7.1M 7.59M 601M Capitalization 38.39M 41.04M 3.25B
Net income 2024 * -6M -6.41M -508M Net income 2025 * -9M -9.62M -762M EV / Sales 2024 * 7.95 x
Net cash position 2024 * 1.8M 1.92M 152M Net Debt 2025 * 200K 214K 16.92M EV / Sales 2025 * 5.43 x
P/E ratio 2024 *
-7.01 x
P/E ratio 2025 *
-5.68 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 68.01%
More Fundamentals * Assessed data

Chart Cerenis Therapeutics

Dynamic Chart

Latest news about Cerenis Therapeutics

Abionyx: positive response from FDA, share price rises CF
ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis CI
Abionyx Pharma: to benefit from a 1ME grant from Bpifrance CF
Abionyx: reduced net loss in 2023 CF
ABIONYX Pharma SA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Abionyx: CSL Behring fails in heart disease trial CF
ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring?S Human-Plasma-Derived Apoa-I, CSL112 CI
Abionyx: former AbbVie executive appointed CMO CF
ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D CI
Abionyx: Successful completion of third GMP batch of CER-001 CF
2,867,986 Ordinary Shares of ABIONYX Pharma SA are subject to a Lock-Up Agreement Ending on 7-DEC-2023. CI
Abionyx: encouraging results in brain fog CF
ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023 CI
Abionyx: promising new results in uveitis CF
ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I CI
More news

Press releases Cerenis Therapeutics

ABIONYX decides on a capital increase with cancellation of preferential subscription rights for the benefit of a category of persons through the issue of shares with warrants for an amount of c.€3.4 million BU
ABIONYX Pharma : has completed a successful pre IND meeting with the FDAfor CER 001 Phase 2b/3 Clinical Trial for Patients with Sepsis PU
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis BU
ABIONYX Pharma has completed a successful pre-IND meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis BU
ABIONYX Pharma Provides an Update on Its Activity and Cash Position for the 1st Quarter 2024 BU
More press releases

News in other languages on Cerenis Therapeutics

Nouvelle avalanche de banquiers centraux
En Direct des Marchés : TotalEnergies, Danone, Orange, Technip Energies, STM, Apple, Bic...
Borsa di Italia: Un'altra valanga di banchieri centrali
Bolsa de Madrid: Otra avalancha de banqueros centrales
ABIONYX Pharma : Informations privilégiées / Autres communiqués
More news

Managers and Directors - Cerenis Therapeutics

Managers TitleAgeSince
Cyrille Tupin CEO
 Chief Executive Officer 48 31/12/06
Emmanuel de Fougeroux DFI
 Director of Finance/CFO - 30/04/08
Renee Benghozi CTO
 Chief Tech/Sci/R&D Officer - 08/02/15
Members of the board TitleAgeSince
Olivier Martinez BRD
 Director/Board Member 54 -
Christian Chavy BRD
 Director/Board Member 75 05/02/15
Cyrille Tupin CEO
 Chief Executive Officer 48 31/12/06
More insiders

Company Profile

ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases. At the end of 2023, the company boasted a portfolio of 3 products in clinical development.
Sector
Biotechnology & Medical Research
Calendar
21/08/2024 - Q2 2024 Sales and Revenue Release
More about the company

Income Statement Evolution

More financial data

Ratings for Cerenis Therapeutics

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.192 EUR
Average target price
11.5 EUR
Spread / Average Target
+864.77%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+16.49% 122B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+21.73% 115B
ARGENX SE Stock argenx SE
+22.88% 26.64B
BIONTECH SE Stock BioNTech SE
-21.81% 19.91B
GENMAB A/S Stock Genmab A/S
-17.03% 16.32B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.81% 15.49B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-44.74% 15.52B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+62.72% 14.83B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.09% 13.67B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABNX Stock
  4. Stock